drugset / Trial / NCT02253927
Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers
NaSingle-groupOpen-labelTreatment
Summary
The primary objective was to explore the relative bioavailability of increasing doses of BILR 355 BS, as a sodium dodecyl sulfate-containing solid formulation (SDS), in combination with ritonavir 100 mg and to explore the dose-concentration proportionality of increasing doses. A secondary objective was to explore the effect of food on the pharmacokinetics of BILR 355 (SDS)
Timeline
- Start
- 2006-05
- Primary completion
- 2006-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BILR 355 | Small molecule | 225 mg | Oral |
| Subject | BILR 355 | Small molecule | 450 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |
Indications
No indication recorded.